Epidemiological characteristics of rotavirus gastroenteritis in China: A systematic review of studies published from 2014 to 2023.

Hum Vaccin ImmunotherJan 7, 2026 (epub)
Clinical ResearchGastroenterologyInfectious DiseasesOpen access

Yanwei Wu, Xinling Liu, Qingmei Leng et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analysed 320 studies published from 2014 to 2023 on rotavirus gastroenteritis (RVGE) incidence, population distribution and genotypes in China. Rotavirus positivity among children was 26.46% in outpatient/emergency settings and 32.85% among inpatients. Genotype patterns shifted over time: after 2018, G9 and P[8] predominated in both children and adults, while G8 increased among children. The review found substantial geographic variation in reported positivity and infection counts, and concluded that RVGE remains a significant burden in China.

Key findings

  • Rotavirus positivity was 26.46% among children attending outpatient/emergency departments and 32.85% among paediatric inpatients.
  • After 2018, G9 accounted for 66.73% of child and 67.43% of adult G genotypes; P[8] accounted for 88.62% and 88.57%, respectively.
  • Among children, G8 increased from 0.89% before 2018 to 5.08% after 2018.
  • The highest reported child positivity rates were in Jilin (48.59%), Shanxi (40.89%) and Xinjiang (37.65%).

Why it matters

The review brings together evidence of substantial RVGE burden and geographic variation in China, alongside changes in circulating genotypes. These patterns are relevant to monitoring disease burden and assessing whether vaccine strains remain aligned with circulating rotavirus types. The findings also underscore the value of consistent surveillance across populations and regions.

What to keep in mind

The review synthesizes published studies, and the abstract notes the absence of a comprehensive detection system in China; reported rates and infection counts may therefore not represent uniform national surveillance.

Source

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.